REGENXBIO Inc. (RGNX) is a publicly traded company in the Unknown sector. Across all available filings, 22 corporate insiders have executed 706 transactions totaling $105.7M, demonstrating a bearish sentiment with -$98.0M in net insider flow. The most recent transaction on Jan 2, 2026 involved a transaction of 18,247 shares valued at $262.8K.
No significant insider buying has been recorded for RGNX in the recent period.
No significant insider selling has been recorded for RGNX in the recent period.
Based on recent SEC filings, insider sentiment for RGNX is bearish with an Insider Alignment Score of 4/100 and a net flow of -$98.0M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at REGENXBIO Inc. (RGNX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 22 insiders are actively trading RGNX stock, having executed 706 transactions in the past 90 days. The most active insider is Kenneth T. Mills (Executive), who has made 158 transactions totaling $27.5M.
Get notified when executives and directors at RGNX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Pakola Steve | Chief Medical Officer | Payment | 18,247 | $14.40 | $262.8K | |
| Jan 2, 2026 | J. Christmas Patrick | Chief Strategy & Legal Officer | Payment | 9,793 | $14.40 | $141.0K | |
| Jan 2, 2026 | Malzahn Craig | Chief Technology Officer | Payment | 1,238 | $14.40 | $17.8K | C-Suite |
| Oct 9, 2025 | Simpson Curran | Executive | Sale | 20,811 | $12.62 | $262.6K | |
| Sep 29, 2025 | Simpson Curran | Executive | Sale | 7,624 | $10.03 | $76.5K | |
| Sep 10, 2025 | Simpson Curran | Executive | Sale | 7,734 | $10.02 | $77.5K | |
| Sep 1, 2025 | Chan Mitchell | Executive | Payment | 4,901 | $8.93 | $43.8K | |
| Sep 1, 2025 | Malzahn Craig | Executive | Payment | 234 | $8.93 | $2.1K | |
| Aug 1, 2025 | J. Christmas Patrick | Executive | Payment | 4,699 | $8.19 | $38.5K | |
| Jul 1, 2025 | Simpson Curran | Executive | Payment | 4,701 | $8.23 | $38.7K | |
| Sep 16, 2024 | Chan Mitchell | Executive | Award | 58,869 | $N/A | $0 | |
| Sep 3, 2024 | N. Karabelas Argeris | Executive | Sale | 9,300 | $11.50 | $107.0K | 10b5-1 |
| Sep 3, 2024 | N. Karabelas Argeris | Executive | Sale | 700 | $12.34 | $8.6K | 10b5-1 |
| Sep 3, 2024 | N. Karabelas Argeris | Executive | Option Exercise | 10,000 | $3.76 | $37.6K | 10b5-1 |
| Aug 8, 2024 | T. Mills Kenneth | Executive | Option Exercise | 36,316 | $0.85 | $30.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 430 | $101.8M | 83.3% |
Exercise(M) | 163 | $14.3M | 11.7% |
Purchase(P) | 3 | $3.9M | 3.1% |
Payment(F) | 24 | $2.2M | 1.8% |
Award(A) | 67 | $153.2K | 0.1% |
Gift(G) | 6 | $0 | 0.0% |
Other(J) | 2 | $0 | 0.0% |
Conversion(C) | 11 | $0 | 0.0% |
Insider selling pressure at REGENXBIO Inc. has increased, with 22 insiders executing 706 transactions across all time. Total sales of $101.8M significantly outpace purchases of $3.9M, resulting in a net outflow of $98.0M. However, 50% of these transactions are pre-scheduled 10b5-1 plans, often used for tax planning or diversification rather than signaling negative outlook.